Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00620633 |
|
Recruitment Status :
Completed
First Posted : February 21, 2008
Last Update Posted : March 2, 2021
|
Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Atara Biotherapeutics
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | February 26, 2021 |
| Actual Study Completion Date : | February 26, 2021 |